Ocular Therapeutix (OCUL) EBITDA Margin (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly EBITDA Margin of 609.34% for Q2 2026, down 10677.0% year-over-year from N/an in Q2 2025, and up 29.59% on a QoQ basis from 865.46% in Q1 2026.
Ocular Therapeutix (OCUL) EBITDA Margin (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported EBITDA Margin for 13 years, with the latest figure at 609.34% in Q2 2026.
- EBITDA Margin for Q2 2026 came in at 609.34%, down 10677.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 603.04% (down 20044.0% YoY), and the FY2025 annual result was 519.75%, down 25018.0% from the prior year.
- EBITDA Margin climbed to 609.34% in Q2 2026, from 865.46% in the prior quarter.
- Over five years, EBITDA Margin peaked at 127.41% in Q3 2023 and troughed at 865.46% in Q1 2026.
- A 5-year average of 323.85% and a median of 239.57% in 2024 frame the typical range for EBITDA Margin.
- The widest annual swing landed in 2022, when EBITDA Margin jumped 14028 bps; it then plunged 38346 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 137.56% in 2022, then climbed by 2 bps to 135.46% in 2023, then plunged by 119 bps to 296.08% in 2024, then plunged by 78 bps to 526.49% in 2025, then dropped by 16 bps to 609.34% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 609.34% in Q2 2026, 865.46% in Q1 2026, and 526.49% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | -609.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -609.34% |
| Mar 31, 2026 | -865.46% |
| Dec 31, 2025 | -526.49% |
| Sep 30, 2025 | -472.35% |
| Jun 30, 2025 | -502.57% |
| Mar 31, 2025 | -597.47% |
| Dec 31, 2024 | -296.08% |
| Sep 30, 2024 | -298.20% |
| Jun 30, 2024 | -265.13% |
| Mar 31, 2024 | -214.00% |
| Dec 31, 2023 | -135.46% |
| Sep 30, 2023 | -127.41% |
| Jun 30, 2023 | -135.45% |
| Mar 31, 2023 | -168.60% |
| Dec 31, 2022 | -137.56% |
| Sep 30, 2022 | -180.06% |
| Jun 30, 2022 | -162.37% |
| Mar 31, 2022 | -135.23% |
| Dec 31, 2021 | -146.64% |
| Sep 30, 2021 | -160.69% |